Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis

PURPOSE: Thalidomide and lenalidomide can alleviate anemia in myelofibrosis. However, their value is undermined by their respective potential to cause peripheral neuropathy and myelosuppression. We therefore evaluated the safety and therapeutic activity of another immunomodulatory drug, pomalidomide...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Tefferi, Ayalew, Verstovsek, Srdan, Barosi, Giovanni, Passamonti, Francesco, Roboz, Gail J., Gisslinger, Heinz, Paquette, Ronald L., Cervantes, Francisco, Rivera, Candido E., Deeg, H. Joachim, Thiele, Juergen, Kvasnicka, Hans M., Vardiman, James W., Zhang, Yanming, Bekele, B. Nebiyou, Mesa, Ruben A., Gale, Robert P., Kantarjian, Hagop M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2009
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979191/
https://ncbi.nlm.nih.gov/pubmed/19652059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.7356
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller